Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

23.11USD
21 Feb 2017
Change (% chg)

$-0.01 (-0.04%)
Prev Close
$23.12
Open
$23.28
Day's High
$23.49
Day's Low
$22.94
Volume
3,934,172
Avg. Vol
5,816,912
52-wk High
$23.49
52-wk Low
$3.55

EXEL.O

Chart for EXEL.O

About

Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $6,479.63
Shares Outstanding(Mil.): 286.46
Dividend: --
Yield (%): --

Financials

  EXEL.O Industry Sector
P/E (TTM): -- 46.85 29.68
EPS (TTM): -0.62 -- --
ROI: -45.55 -3.61 13.06
ROE: -- 5.27 14.19

BRIEF-Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab

* Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab in refractory metastatic urothelial carcinoma and other genitourinary tumors

Feb 17 2017

BRIEF-Exelixis and Takeda enter into exclusive licensing agreement

* Exelixis and Takeda enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in Japan

Jan 30 2017

BRIEF-Genentech withdraws counterclaim against Exelixis in JAMS arbitration

* Update on dispute between Exelixis and Genentech, a member of the Roche group

Jan 09 2017

BRIEF-Exelixis announces Q3 and YTD 2016 financial results

* Exelixis announces third quarter and year to date 2016 financial results and provides corporate update

Nov 03 2016

BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib

* Cabozantinib met primary endpoint of improving progression-free survival as compared to Sunitinib

Oct 11 2016

BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib

* Ipsen and its partner Exelixis announce positive results from Phase 2 CABOSUN Trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

Oct 10 2016

BRIEF-Exelixis announces Phase 1 trial results for Cabozantinib in combination with Nivolumab in advanced Genitourinary tumors

* Says findings will be presented during a poster discussion session on October 9

Oct 07 2016

BRIEF-Exelixis elects Julie Anne Smith to board

* Exelixis elects Julie Anne Smith to its board of directors Source text for Eikon: Further company coverage:

Sep 26 2016

BRIEF-Exelixis announces redemption of remaining 4.25 convertible senior subordinated notes

* Exelixis announces redemption of all remaining 4.25% convertible senior subordinated notes due 2019

Aug 24 2016

More From Around the Web

Competitors

Earnings vs. Estimates